{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Algernon Pharmaceuticals Announces Private Placement - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"AAxdVTsdXP\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-announces-private-placement\/\">Algernon Pharmaceuticals Announces Private Placement<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-announces-private-placement\/embed\/#?secret=AAxdVTsdXP\" width=\"600\" height=\"338\" title=\"&#8220;Algernon Pharmaceuticals Announces Private Placement&#8221; &#8212; Market Newsdesk\" data-secret=\"AAxdVTsdXP\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"VANCOUVER, British Columbia, March 02, 2021 (GLOBE NEWSWIRE) &#8212; Algernon Pharmaceuticals Inc.\u00a0(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the \u201cCompany\u201d or \u201cAlgernon\u201d) a clinical stage pharmaceutical development company is\u00a0pleased to announce a non-brokered private placement of 10,800,000 units for total proceeds\u00a0of CAD $2,700,000. Each unit is comprised of one common share at a price of $.25 and one share purchase warrant exercisable at a price of $0.40 per share for a period of 24 months from the closing date (the \u201cWarrants\u201d). The Warrants are subject to accelerated expiry in the event the daily volume weighted average trading price of the Common Shares equals or exceeds CAD $0.80 on the Canadian Securities Exchange (the \u201cExchange\u201d) (or such other exchange on which the &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzM4MiM0MDQ1NjYxIzIwOTIzNjc="}